



## Zynerba Pharmaceuticals to Present at the Canaccord Genuity 41st Annual Growth Conference

August 4, 2021

DEVON, Pa., Aug. 04, 2021 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, today announced that Company management will participate in a fireside chat during the Canaccord Genuity 41<sup>st</sup> Annual Growth Conference being held virtually on Wednesday, August 11, 2021 at 1:30 p.m. ET.

Investors interested in arranging a virtual meeting with the Company's management during the conference should contact the Canaccord Genuity conference coordinator. A webcast of the fireside chat will be available under the Events & Webcasts tab of the Investors section of the Zynerba website at [www.zynerba.com](http://www.zynerba.com). An archived replay will be available on the Company's website following the event for 60 days.

### **About Zynerba Pharmaceuticals, Inc.**

Zynerba Pharmaceuticals is the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders. We are committed to improving the lives of patients and their families living with severe, chronic health conditions including Fragile X syndrome, autism spectrum disorder, 22q11.2 deletion syndrome, and a heterogeneous group of rare and ultra-rare epilepsies known as developmental and epileptic encephalopathies. Learn more at [www.zynerba.com](http://www.zynerba.com) and follow us on Twitter at @ZynerbaPharma.

### **Cautionary Note on Forward-Looking Statements**

This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. We may, in some cases, use terms such as "predicts," "believes," "potential," "proposed," "continue," "estimates," "anticipates," "expects," "plans," "intends," "may," "could," "might," "will," "should" or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. Such statements are subject to numerous important factors, risks and uncertainties that may cause actual events or results to differ materially from the Company's current expectations. These and other risks are described in the Company's periodic reports, including the annual report on Form 10-K, quarterly reports on Form 10-Q and current reports on Form 8-K, filed with or furnished to the Securities and Exchange Commission and available at [www.sec.gov](http://www.sec.gov). Any forward-looking statements that the Company makes in this press release speak only as of the date of this press release. The Company assumes no obligation to update forward-looking statements whether as a result of new information, future events or otherwise, after the date of this press release.

### **Investor Contact**

Peter Vozzo  
Westwicke/ICR  
Office: 443-213-0505  
Cell: 443-377-4767  
[peter.vozzo@westwicke.com](mailto:peter.vozzo@westwicke.com)